Bank Pictet & Cie Europe AG Decreases Stock Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

Bank Pictet & Cie Europe AG lowered its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 2.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,805 shares of the company’s stock after selling 89 shares during the quarter. Bank Pictet & Cie Europe AG’s holdings in Vaxcyte were worth $435,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its holdings in shares of Vaxcyte by 15.2% in the 1st quarter. Vanguard Group Inc. now owns 9,737,254 shares of the company’s stock valued at $665,152,000 after buying an additional 1,284,883 shares in the last quarter. RA Capital Management L.P. boosted its stake in Vaxcyte by 4.0% in the first quarter. RA Capital Management L.P. now owns 8,203,754 shares of the company’s stock valued at $560,398,000 after acquiring an additional 312,500 shares in the last quarter. Janus Henderson Group PLC grew its holdings in Vaxcyte by 9.9% in the first quarter. Janus Henderson Group PLC now owns 7,673,868 shares of the company’s stock worth $524,117,000 after purchasing an additional 692,492 shares during the last quarter. Capital Research Global Investors increased its position in shares of Vaxcyte by 20.4% during the first quarter. Capital Research Global Investors now owns 4,140,521 shares of the company’s stock worth $282,839,000 after purchasing an additional 700,414 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its holdings in shares of Vaxcyte by 18.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,176,181 shares of the company’s stock valued at $216,966,000 after purchasing an additional 498,359 shares during the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Insider Buying and Selling at Vaxcyte

In other news, SVP Elvia Cowan sold 5,000 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $107.67, for a total value of $538,350.00. Following the sale, the senior vice president now owns 12,723 shares in the company, valued at $1,369,885.41. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Vaxcyte news, SVP Elvia Cowan sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 3rd. The stock was sold at an average price of $107.67, for a total value of $538,350.00. Following the completion of the transaction, the senior vice president now directly owns 12,723 shares of the company’s stock, valued at approximately $1,369,885.41. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Andrew Guggenhime sold 42,000 shares of the company’s stock in a transaction that occurred on Friday, October 18th. The stock was sold at an average price of $115.39, for a total value of $4,846,380.00. Following the completion of the sale, the chief financial officer now owns 90,383 shares in the company, valued at approximately $10,429,294.37. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 92,098 shares of company stock worth $9,937,773. Insiders own 3.10% of the company’s stock.

Vaxcyte Trading Down 2.4 %

Shares of NASDAQ:PCVX opened at $112.66 on Wednesday. Vaxcyte, Inc. has a twelve month low of $45.61 and a twelve month high of $121.06. The company has a market cap of $12.57 billion, a PE ratio of -24.07 and a beta of 0.99. The company’s 50 day moving average is $104.02 and its 200 day moving average is $83.43.

Vaxcyte (NASDAQ:PCVX) last issued its earnings results on Tuesday, August 6th. The company reported ($1.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.14) by $0.04. During the same quarter in the previous year, the firm posted ($0.70) EPS. Equities research analysts predict that Vaxcyte, Inc. will post -4.33 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on PCVX. Bank of America upped their target price on Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a research report on Wednesday, September 4th. Leerink Partners upped their price objective on shares of Vaxcyte from $106.00 to $153.00 and gave the company an “outperform” rating in a report on Tuesday, September 3rd. BTIG Research lifted their target price on shares of Vaxcyte from $98.00 to $160.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Mizuho upped their price target on shares of Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research note on Tuesday, September 10th. Finally, Needham & Company LLC lifted their price objective on shares of Vaxcyte from $95.00 to $140.00 and gave the stock a “buy” rating in a research note on Tuesday, September 3rd. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average target price of $147.50.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.